Lit­tle Abi­vax sees volatile shares rock­et up on a (very ear­ly-stage) re­port of an HIV break­through

Abi­vax is wit­ness­ing the lat­est gy­ra­tion in its stock price af­ter claim­ing it’s gath­ered ev­i­dence of suc­cess in elim­i­nat­ing a sig­nif­i­cant amount of the reser­voirs of HIV that linger in pa­tients. But it’s ear­ly days yet for this drug and a com­pa­ny that has seen plen­ty of ups and downs over the last year.

The Paris-based biotech {$AB­VX.PA} says that in a small study with 30 HIV pa­tients — split 3-1 on drug and place­bo — ABX464 was com­bined with their cur­rent an­ti­retro­vi­ral reg­i­men to test its ef­fect af­ter 28 days.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.